Vaccinex, Inc. (NASDAQ:VCNX) Short Interest Update

Vaccinex, Inc. (NASDAQ:VCNX) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 20,100 shares, an increase of 118.5% from the May 31st total of 9,200 shares. Currently, 2.6% of the company’s shares are sold short. Based on an average daily trading volume, of 18,200 shares, the short-interest ratio is currently 1.1 days.

Hedge Funds Weigh In On Vaccinex

A hedge fund recently bought a new stake in Vaccinex stock. Armistice Capital LLC acquired a new position in shares of Vaccinex, Inc. (NASDAQ:VCNX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 680,000 shares of the company’s stock, valued at approximately $768,000. Armistice Capital LLC owned about 15.45% of Vaccinex at the end of the most recent quarter. 50.11% of the stock is currently owned by institutional investors and hedge funds.

Vaccinex Price Performance

Shares of Vaccinex stock traded down $0.10 during midday trading on Friday, reaching $6.08. The company had a trading volume of 2,560 shares, compared to its average volume of 15,077. Vaccinex has a fifty-two week low of $4.43 and a fifty-two week high of $83.56. The stock has a fifty day moving average price of $5.97 and a 200 day moving average price of $7.51.

Vaccinex (NASDAQ:VCNX) last released its earnings results on Wednesday, May 15th. The company reported ($2.94) earnings per share (EPS) for the quarter. The company had revenue of $0.10 million for the quarter.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.